1.64
0.03 (1.86%)
| Previous Close | 1.61 |
| Open | 1.59 |
| Volume | 1,406,805 |
| Avg. Volume (3M) | 2,061,563 |
| Market Cap | 482,230,528 |
| Price / Earnings (Forward) | 9.14 |
| Price / Sales | 122.78 |
| Price / Book | 13.74 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -1,910.67% |
| Diluted EPS (TTM) | -0.470 |
| Quarterly Revenue Growth (YOY) | -3.10% |
| Total Debt/Equity (MRQ) | 8.25% |
| Current Ratio (MRQ) | 4.76 |
| Operating Cash Flow (TTM) | -75.70 M |
| Levered Free Cash Flow (TTM) | -51.40 M |
| Return on Assets (TTM) | -39.95% |
| Return on Equity (TTM) | -136.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Precigen, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.97% |
| % Held by Institutions | 66.16% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Patient Capital Management, Llc | 31 Dec 2024 | 17,881,246 |
| Iridian Asset Management Llc/Ct | 31 Dec 2024 | 5,241,922 |
| Lexaurum Advisors, Llc | 31 Dec 2024 | 691,544 |
| Gmt Capital Corp | 31 Dec 2024 | 668,830 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (HC Wainwright & Co., 265.85%) | Buy |
| 6.00 (Citizens Capital Markets, 265.85%) | Buy | |
| Median | 6.00 (265.85%) | |
| Low | 5.00 (JMP Securities, 204.88%) | Buy |
| Average | 5.67 (245.73%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens Capital Markets | 20 Mar 2025 | 6.00 (265.85%) | Buy | 1.80 |
| HC Wainwright & Co. | 20 Mar 2025 | 6.00 (265.85%) | Buy | 1.80 |
| 23 Jan 2025 | 6.00 (265.85%) | Buy | 1.34 | |
| JMP Securities | 14 Jan 2025 | 5.00 (204.88%) | Buy | 1.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Mar 2025 | Announcement | Precigen Reports Full Year 2024 Financial Results and Business Updates |
| 25 Feb 2025 | Announcement | FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 |
| 13 Jan 2025 | Announcement | Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference |
| 09 Jan 2025 | Announcement | Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |